mTOR

In one line: mTOR is an ancient nutrient-sensing kinase — the switch a cell uses to choose between growing now and lasting longer. A molecule scraped from the soil of Easter Island (rapamycin) led us to it; dialing the switch down extends lifespan across yeast, worms, flies, and even mice, while the same switch jammed on helps drive cancer.

---

The gene

MTOR sits near the very tip of the short arm of chromosome 1 (band 1p36.22) and encodes a large serine/threonine kinase of the PIKK family. It is best understood not as a single machine but as the catalytic core of two of them: mTOR complex 1 (mTORC1) — defined by its partner RAPTOR — and mTOR complex 2 (mTORC2) — defined by RICTOR. Together they make mTOR the cell's master switch between anabolism (build) and catabolism (conserve and recycle). When nutrients are plentiful, the switch says grow; when they are scarce, it steps back and lets the cell live off its own reserves. Almost every eukaryote — yeast to human — runs a version of it.

The hunt (soil → yeast → human)

The story runs backwards from most gene stories: the drug came before the gene. In the 1970s, a soil sample from Rapa Nui (Easter Island) yielded the bacterium Streptomyces hygroscopicus, which produced a potent antifungal. Vézina, Kudelski, and Sehgal at Ayerst named it rapamycin, after the island (published 1975). It had a strange talent — it stopped cells from dividing — but nobody knew what it grabbed inside.

To find the target, the field turned to budding yeast. In 1991, Joseph Heitman, Rao Movva, and Michael N. Hall (Basel) dosed yeast with rapamycin, watched them arrest, then screened for mutants that could grow anyway. Every escape mutation landed on the same two genes, which they named TOR — Target Of Rapamycin. (Hall received the 2017 Lasker Basic Medical Research Award for this line of work.) The mammalian ortholog was then cloned independently by three groups in 1994–95 — Sabatini's RAFT1 (Cell 1994), Brown & Schreiber's FRAP (Nature 1994), and Sabers & Abraham's mTOR (JBC 1995) — each fishing the protein out by its rapamycin-binding activity. The switch was the same from yeast to human, barely redrawn in a billion years of evolution.

The mechanism

mTORC1 is the sensor. Docked on the surface of the lysosome, it integrates three streams of information: amino acids (via the Rag GTPases/Ragulator that recruit it to the lysosome), growth-factor signals (insulin → PI3K → AKT, which relieves the TSC1/TSC2 brake on the small GTPase Rheb), and the cell's energy status (via AMPK). When all three read plenty, mTORC1 switches on and commits the cell to growth: it phosphorylates S6K1 and 4E-BP1 to drive protein synthesis, ramps up lipid and nucleotide production, and — at the same moment — shuts off autophagy (by phosphorylating ULK1/ATG13), the recycling program a cell relies on during famine. Grow, or clean house: it cannot do both. mTORC2 works the other side — phosphorylating AKT at Ser473, plus SGK1 and PKC, to tune survival and cell shape.

Rapamycin doesn't act alone. It first binds the small protein FKBP12; the FKBP12–rapamycin complex then wedges into mTOR's FRB domain and allosterically inhibits mTORC1 specifically — not the active site, and not mTORC2 (which is acutely insensitive; only prolonged treatment can disrupt it in some cell types). That selectivity is the whole reason rapamycin is both a useful drug and a blunt one.

Aging & lifespan (the surprise)

Turn the switch down, and life gets longer — repeatedly, across the tree of life. Reduced TOR signaling extends lifespan in yeast, in C. elegans worms (Vellai, 2003), and in Drosophila flies (Bjedov, 2010). Then came the hardest test. In 2009, the NIA Interventions Testing Program reported (Harrison et al., Nature) that rapamycin fed late in life — starting at 600 days, roughly a human's sixties — extended the lifespan of genetically heterogeneous mice by about 9–14%. It was the first pharmacological agent ever shown to extend the lifespan of a mammal. Caloric restriction, the oldest longevity intervention we know, appears to act in part through the very same pathway.

Cancer (the switch stuck on)

A growth switch has an obvious dark side. The circuit feeding mTOR — PI3K, AKT, and the tumor suppressor PTEN — is among the most frequently dysregulated in human cancer; lose the brakes and the cell keeps building itself. So rapamycin's chemical descendants ("rapalogs") became approved cancer drugs: temsirolimus (advanced renal cell carcinoma, FDA 2007) and everolimus (RCC 2009; pancreatic neuroendocrine tumors 2011; HR+ advanced breast cancer with exemestane 2012). The clearest human "mTOR-pathway disease" is tuberous sclerosis complex, where a germline loss of TSC1 or TSC2 removes the brake on Rheb, leaving mTORC1 constitutively on and sprouting benign tumors (brain SEGAs, kidney angiomyolipomas) — which everolimus can shrink.

The frontier

The open question is whether we can borrow the longevity without the danger. Rapamycin is blunt: hold the switch down long enough and you begin to disturb mTORC2, producing side effects such as glucose intolerance — and even on mTORC1 it inhibits some outputs (notably 4E-BP1) incompletely. Two responses are in play. First, third-generation, mTORC1-selective "bi-steric" inhibitors (e.g. RMC-5552) engineered to press complex 1 alone and spare complex 2. Second, dosing strategy — intermittent, low-dose regimens meant to keep the beneficial mTORC1 effect while limiting the rest. On the aging side, rapamycin is now the leading candidate geroprotector: it's being tested in healthy middle-aged companion dogs (the Dog Aging Project / TRIAD trial), and low-dose mTOR inhibition has already been shown to sharpen the immune systems of elderly people (Mannick et al., 2014 and 2018). But the human anti-aging benefit remains unproven — the trials are ongoing, and the molecule under test is the same sirolimus approved back in 1999 for transplant rejection.

Sources

Full claim-by-claim evidence is in references.md. Primary/authoritative anchors:

• MTOR gene (location 1p36.22, kinase): OMIM 601231 — https://omim.org/entry/601231 ; UniProt P42345 — https://www.uniprot.org/uniprotkb/P42345/entry
• Rapamycin isolated from Rapa Nui soil (1975): Vézina, Kudelski & Sehgal, J Antibiot 28:721 — https://pubmed.ncbi.nlm.nih.gov/1102508/
• Yeast TOR discovered (1991): Heitman, Movva & Hall, Science 253:905 — https://pubmed.ncbi.nlm.nih.gov/1715094/
• Mammalian ortholog cloned (1994–95): Sabatini et al. (RAFT1), Cell — https://pubmed.ncbi.nlm.nih.gov/7518356/ ; Brown et al. (FRAP), Nature — https://www.nature.com/articles/369756a0 ; Sabers et al. (mTOR), JBC — https://pubmed.ncbi.nlm.nih.gov/7822316/
• "mTOR = mechanistic" nomenclature: Laplante & Sabatini, Biochem Soc Trans 2013 — https://pubmed.ncbi.nlm.nih.gov/23863150/
• Signaling reviews (complexes, inputs, outputs): Saxton & Sabatini, Cell 2017 — https://pubmed.ncbi.nlm.nih.gov/28388417/ ; Laplante & Sabatini, Cell 2012 — https://pmc.ncbi.nlm.nih.gov/articles/PMC3331679/
• Amino-acid sensing at the lysosome (Rag GTPases): Sancak et al., Cell 2010 — https://pmc.ncbi.nlm.nih.gov/articles/PMC3024592/
• TSC2 is a GAP for Rheb: Inoki et al., Genes Dev 2003 — https://pmc.ncbi.nlm.nih.gov/articles/PMC196227/
• Rapamycin mechanism (FKBP12 → FRB, mTORC1-selective): Yang et al., Nature 2013 — https://pmc.ncbi.nlm.nih.gov/articles/PMC4512754/ ; mTORC2 acute insensitivity — Sarbassov et al., Mol Cell 2006 — https://pubmed.ncbi.nlm.nih.gov/16603397/
• Rapamycin extends mouse lifespan (late-life, +9–14%): Harrison et al., Nature 2009 — https://pubmed.ncbi.nlm.nih.gov/19587680/ ; worms — Vellai et al. 2003 — https://pubmed.ncbi.nlm.nih.gov/14668850/ ; flies — Bjedov et al. 2010 — https://pmc.ncbi.nlm.nih.gov/articles/PMC2824086/
• Rapalogs in cancer: temsirolimus FDA summary — https://pmc.ncbi.nlm.nih.gov/articles/PMC3227966/ ; everolimus (Afinitor) approval history — https://www.drugs.com/history/afinitor.html ; mTOR inhibitors in TSC — https://pmc.ncbi.nlm.nih.gov/articles/PMC3520048/
• State of the art / geroscience: bi-steric RMC-5552 — Liao et al., J Med Chem 2023 — https://pmc.ncbi.nlm.nih.gov/articles/PMC9841523/ ; mTOR & aging review — Nature Aging 2023 — https://www.nature.com/articles/s43587-023-00416-y ; Dog Aging Project TRIAD — https://dogagingproject.org/triad ; human immune trials — Mannick et al., Sci Transl Med 2014 — https://www.science.org/doi/10.1126/scitranslmed.3009892 and 2018 — https://www.science.org/doi/10.1126/scitranslmed.aaq1564
• Hall's 2017 Lasker Award: Lasker Foundation — https://laskerfoundation.org/awards/show/nutrient-activated-tor-proteins-regulate-cell-growth/

Accuracy notes (the traps this episode states carefully):

1. The "m" in mTOR now stands for mechanistic, not "mammalian." TOR is present in all eukaryotes; the rename (Laplante & Sabatini, 2013) reflects that it is the mechanistic target of rapamycin everywhere, not just in mammals.
2. Yeast TOR and mammalian mTOR were two separate discoveries. Hall's group found TOR in yeast (1991); the mammalian protein was cloned by three labs in 1994–95 (Sabatini/Snyder, Brown/Schreiber, Sabers/Abraham). The episode keeps them as distinct events and does not credit "the discovery of mTOR" to one person.
3. Rapamycin acutely inhibits mTORC1 only — via FKBP12 binding the FRB domain, an allosteric action, not ATP-competitive. mTORC2 is acutely insensitive (prolonged treatment can disrupt it in some cells). ATP-site inhibitors like Torin1 block both complexes.
4. Rapalogs are cytostatic, not curative. In most solid tumors they slow progression (extend progression-free survival) rather than shrink tumors; single-agent efficacy outside RCC/pNET/TSC is modest. They are not a "cancer cure."
5. The mouse result is a ~9–14% late-life extension, not a doubling of lifespan — and it was measured with rapamycin started late in life.
6. The human anti-aging benefit is unproven. Evidence so far is animal lifespan data plus improved immune biomarkers in the elderly; the dog and human trials are ongoing. The candidate drug (sirolimus) is the same molecule approved in 1999 for transplant rejection.